This multiple choice assessment focuses on the AIGP body of knowledge

 

Format: Multiple Choice

The result will be provided immediately, with details on all questions.

1) Which of the following is not one of the three three distinct levels of testing, which form the key objectives of the NIST's Assessing Risks and Impacts of AI (ARIA) program.

Scenario based questions: Please use the following scenario to answer questions 2-4

MAPO, a multinational health care company with a presence in the U.S., India and South Africa, has a strong track record of adhering to regulatory requirements and ensuring patient safety. With the increasing integration of AI in health care for diagnostics, personalized treatment and operational efficiency, the organization recognizes the need to enhance its governance processes.

MAPO has an enterprise risk management function overseeing privacy and security risk management locally for in-house and third-party applications across its markets. High-risk scenarios are escalated to headquarters for centralized risk analysis.

 

Despite robust processes, the increasing adoption of AI poses challenges in taking stock of AI and managing AI risks effectively. Senior management is concerned with the potential AI risk but is keenly aware of the benefits of leveraging AI and is under pressure to keep pace with competitors. In response, they appoint Anna, who has worked for the company for five years in privacy risk management and has a keen interest in AI governance, to lead the AI governance office. Anna’s task is to propose a governance strategy aligning with industry best practices while reflecting MAPO’s commitment to transparency, accountability and patient safety. Anna’s proposal should also address the difficulties in tracking all AI applications within the organization, ensuring that the governance strategy provides a framework for identifying, assessing and managing AI risks across MAPO’s operations in the U.S., India and South Africa. Additionally, the strategy should outline clear guidelines for integrating AI capabilities into existing applications, emphasizing the importance of ethical considerations, patient privacy and regulatory compliance.

2) What is a primary consideration for Anna when tailoring AI governance to the organization?

3) To strengthen the AI governance program early in its build-out, Tochi must do which of the following?

4) Which of the following describes MAPO’s governance model?

Which of the following is not an important point in business case for AI Governance?